Companies › ImmunoGenesis
3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Evofosfamide Hypoxia-inducible factor 1-alpha (HIF-1α) inhibitor; prodrug activated under hypoxic condi | HIF1A | Phase 1 | Metastatic Prostate Cancer | Oct 2027 |
| Zalifrelimab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 1 | Metastatic Prostate Cancer; Metastatic Soft Tissue Sarcoma; Diffuse Intrinsic Pontine Glioma | Oct 2027 |
| IMGS-001 | – | Phase 1 | Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04028063 | Zalifrelimab | Phase 2 | Metastatic Soft Tissue Sarcoma | Oncology | Apr 2027 |
| NCT04943848 | Zalifrelimab | Phase 1 | Diffuse Intrinsic Pontine Glioma | Oncology | Sep 2027 |
| NCT06782555 | Evofosfamide | Phase 1 | Metastatic Prostate Cancer | Oncology | Oct 2027 |
| NCT06782555 | Zalifrelimab | Phase 1 | Metastatic Prostate Cancer | Oncology | Oct 2027 |
| NCT06014502 | IMGS-001 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.